807642-52-0

Usage

Uses

Used in Pharmaceutical Research:
(2E)-1-(4-aminophenyl)-3-(2-methoxyphenyl)prop-2-en-1-one is utilized as a building block in pharmaceutical research for the development of new pharmaceutical drugs. Its structural features and functional groups make it a promising candidate for creating compounds that can interact with biological targets, potentially leading to novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, (2E)-1-(4-aminophenyl)-3-(2-methoxyphenyl)prop-2-en-1-one serves as a valuable intermediate. Its presence in the synthesis process can facilitate the creation of a variety of complex organic molecules, contributing to the advancement of chemical libraries and the discovery of new chemical entities.
Used in the Development of Organic Materials:
(2E)-1-(4-aminophenyl)-3-(2-methoxyphenyl)prop-2-en-1-one may also be employed in the development of organic materials. Its unique chemical properties can be leveraged to create materials with specific characteristics, such as improved conductivity, stability, or reactivity, which can be applied across various industries.
Used as a Catalyst in Chemical Reactions:
Furthermore, (2E)-1-(4-aminophenyl)-3-(2-methoxyphenyl)prop-2-en-1-one has the potential to be used as a catalyst in chemical reactions. Its ability to participate in and accelerate certain chemical processes can enhance the efficiency of industrial chemical production, making it a valuable component in the development of more sustainable and cost-effective chemical processes.

Upstream product

• 99-92-3 p-aminobenzophenone 
• 135-02-4 ortho-anisaldehyde 

Downstream Products

• 1151741-86-4 2-bromo-N-(4-((E)-3-(2-methoxyphenyl)acryloyl)phenyl)acrylamide 

Relevant academic research and scientific papers

ADME properties, bioactivity and molecular docking studies of 4-amino-chalcone derivatives: new analogues for the treatment of Alzheimer, glaucoma and epileptic diseases

In this study, in vitro inhibition effects of (E)-1-(4-aminophenyl)-3-(aryl) prop-2-en-1-one (4-amino-chalcones) derivatives (3a–o) on acetylcholinesterase (AChE) enzyme and human erythrocyte carbonic anhydrase I and II isoenzymes (hCA I- II) were investigated. And also, the biological activities of 4-amino-chalcone derivatives against enzymes which names are acetylcholinesterase (PDB ID: 1OCE), human Carbonic Anhydrase I (PDB ID: 2CAB), human carbonic anhydrase II (PDB ID: 3DC3), were compared. After the results obtained, ADME/T analysis was performed in order to use 4-amino-chalcone derivatives as a drug in the future. Effective inhibitors of carbonic anhydrase I and II isozymes (hCAI and II) and acetylcholinesterase (AChE) enzymes with Ki values in the range of 2.55 ± 0.35–11.75 ± 3.57?nM for hCA I, 4.31 ± 0.78–17.55 ± 5.86?nM for hCA II and 96.01 ± 25.34–1411.41 ± 32.88?nM for AChE, respectively, were the 4-amino-chalcone derivatives (3a–o) molecules.

Design and synthesis of new coumarin–chalcone/NO hybrids of potential biological activity

Abstract: This study aims at investigating a synthesis approach based on molecular hybridization strategy through grafting an nitric oxide-releasing moiety, oxime, to coumarin–chalcone hybrids. In vitro anti-proliferative activity of some of the prepared compounds showed moderate activity (growth inhibition values = 45.85, 40.86, 39.25 for compound 8a against leukemia, Central Nervous system and breast cancer cells, respectively). Also, IC50 = 9.62 and 14.40 for compounds 8h and 8f, respectively against breast Michigan Cancer Foundation-7 cell lines. The antibacterial screening results suggest a possible role for nitric oxide in enhancement of the antibacterial activity where nitric oxide is not the only factor but other factors like physicochemical properties should be investigated for their potential role on the activity.

Design and synthesis of chalcone derivatives as inhibitors of the ferredoxin - Ferredoxin-NADP+ reductase interaction of Plasmodium falciparum: Pursuing new antimalarial agents

Some chalcones have been designed and synthesized using Claisen-Schmidt reactions as inhibitors of the ferredoxin and ferredoxin-NADP+ reductase interaction to pursue a new selective antimalaria agent. The synthesized compounds exhibited inhibition interactions between PfFd-PfFNR in the range of 10.94%-50%. The three strongest inhibition activities were shown by (E)-1-(4-aminophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (50%), (E)-1-(4-aminophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one (38.16%), and (E)-1-(4-aminophenyl)-3-(2,3-dimethoxyphenyl)prop-2-en-1-one (31.58%). From the docking experiments we established that the amino group of the methoxyamino chlacone derivatives plays an important role in the inhibition activity by electrostatic interaction through salt bridges and that it forms more stable and better affinity complexes with FNR than with Fd.

Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents

Major anti-inflammatory agents, steroids and cyclooxygenase, were proved to have serious side effects. Here, a series of chalcone derivatives were synthesized and screened for anti-inflammatory activities. QSAR study revealed that the presence of electron-withdrawing groups in B-ring and electron-donating groups in A-ring of chalcones was important for inhibition of LPS-induced IL-6 expression. Further, compounds 22, 23, 26, 40, and 47 inhibited TNF-α and IL-6 release in a dose-dependent manner and decreased LPS-induced TNF-α, IL-1β, IL-6, IL-12, and COX-2 mRNA production. Mechanistically, compounds 23 and 26 interfered with JNK/NF-κB signaling and dose-dependently prevented ERK and p38 activation. In addition, 23 and 26 exhibited a significant protection against LPS-induced death and were able to block high glucose-activated cytokine profiles in macrophages. Together, these data show a series of anti-inflammatory chalcones with potential therapeutic effects in inflammatory diseases.

Hybrid α-bromoacryloylamido chalcones. Design, synthesis and biological evaluation

Research into the anti-tumor properties of chalcones has received significant attention over the last few years Two novel large series of α-bromoacryloylamido chalcones 1a-m and 2a-k containing a pair of Michael acceptors in their structures, corresponding to the α-bromoacryloyl moiety and the α,β-unsaturated ketone system of the chalcone framework, were synthesized and evaluated for antiproliferative activity against five cancer cell lines. Such hybrid derivatives demonstrated significantly increased anti-tumor activity compared with the corresponding amino chalcones. The most promising lead molecules were 1k, 1m and 2j, which had the highest activity toward the five cell lines. Flow cytometry with K562 cells showed that the most active compounds resulted in a large proportion of the cells entering in the apoptotic sub-G0-G1 peak. Moreover, compound 1k induced apoptosis through the mitochondrial pathway and activated caspase-3.